Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Haemodialysis (HD) patients have an increased risk of death due to bacteraemia; with central venous catheters for dialysis, being a key risk factor. The coronavirus-19 (COVID -19) pandemic further accelerated mortality and morbidity rates in these patients, partly due to co-morbidities and regular hospital visits for dialysis. We analysed the prevalence of bacteraemias in HD patients between 2019-2024, specifically assessing type and source of organism, and antibiotic resistance.
HD patients with a bacteraemia between 2019-2024 were identified from the Microbiology and Renal databases. Data included causative organism, antibiotic sensitivity, type of HD access, source of bacteraemia and patient outcome. Contaminants and repeat positive cultures within the space of one week which grew the same organism were excluded from the analyses.
423 bacteraemias were recorded, of which 177 were not repeats, or contaminants. 74% were line associated, 2% were from AV fistulae, the rest were from other sources e.g osteomyelitis.
72.8% were Gram positive, 24.2% were Gram negative and 0.2% were fungi.
There was an increased number of bacteraemias in 2020 and 2021 (Fig. 1).
The prevalence of Enterococci was greatest in 2020 (Fig. 2).
Of the Gram positives, 40.6% were coagulase positive, 43.7% were coagulase negative, and 9.3% were enterococci. In Gram positive organisms, apart from one case of Microbacterium sp., Vancomycin resistance was only seen with enterococci, of which 58% were Vancomycin resistant.
We found an increase in bacteraemias in 2020-2021. It coincided with the start of the pandemic. It is not clear whether/if this was related to COVID-19, but it is interesting to see that it settled over the next two years back towards ‘baseline’. This would have been around the time that COVID vaccination was being rolled out, and the dialysis patients, in view of being in the vulnerable group, were given priority for this.
Vancomycin is the empirical antibiotic of choice for Gram positive organisms in our unit and 91% of Gram positive isolates were Vancomycin sensitive. The ‘spike’ in VREs in 2020 highlights the importance of anti-microbial stewardship and continued surveillance to detect development of resistance in order to adjust anti-microbial guidelines if needed.
